203 related articles for article (PubMed ID: 38170620)
21. Antibody-Drug Conjugates: Ushering in a New Era of Cancer Therapy.
Hurwitz J; Haggstrom LR; Lim E
Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631232
[TBL] [Abstract][Full Text] [Related]
22. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
23. Elucidating Novel Targets for Ovarian Cancer Antibody-Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity.
Onyido EK; James D; Garcia-Parra J; Sinfield J; Moberg A; Coombes Z; Worthington J; Williams N; Francis LW; Conlan RS; Gonzalez D
Antibodies (Basel); 2023 Oct; 12(4):. PubMed ID: 37873862
[TBL] [Abstract][Full Text] [Related]
24. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
[TBL] [Abstract][Full Text] [Related]
25. Understanding the promising role of antibody drug conjugates in breast and ovarian cancer.
Babbar R; Vanya ; Bassi A; Arora R; Aggarwal A; Wal P; Dwivedi SK; Alolayan S; Gulati M; Vargas-De-La-Cruz C; Behl T; Ojha S
Heliyon; 2023 Nov; 9(11):e21425. PubMed ID: 38027672
[TBL] [Abstract][Full Text] [Related]
26. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
27. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
28. Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy.
Hasan M; Alam S; Poddar SK
Curr Clin Pharmacol; 2018; 13(4):236-251. PubMed ID: 30073930
[TBL] [Abstract][Full Text] [Related]
29. Unlocking the potential of antibody-drug conjugates for cancer therapy.
Drago JZ; Modi S; Chandarlapaty S
Nat Rev Clin Oncol; 2021 Jun; 18(6):327-344. PubMed ID: 33558752
[TBL] [Abstract][Full Text] [Related]
30. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
31. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
Deng S; Lin Z; Li W
Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
[TBL] [Abstract][Full Text] [Related]
32. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
[TBL] [Abstract][Full Text] [Related]
33. Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs.
Díaz-Rodríguez E; Gandullo-Sánchez L; Ocaña A; Pandiella A
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008318
[TBL] [Abstract][Full Text] [Related]
34. The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review.
Filis P; Zerdes I; Soumala T; Matikas A; Foukakis T
Crit Rev Oncol Hematol; 2023 Dec; 192():104189. PubMed ID: 37866413
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.
Nguyen TD; Bordeau BM; Balthasar JP
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765668
[TBL] [Abstract][Full Text] [Related]
36. Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers.
Esapa B; Jiang J; Cheung A; Chenoweth A; Thurston DE; Karagiannis SN
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980732
[TBL] [Abstract][Full Text] [Related]
37. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
38. Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals.
McNamara B; Chang Y; Goreshnik A; Santin AD
Int J Womens Health; 2023; 15():1353-1365. PubMed ID: 37663226
[TBL] [Abstract][Full Text] [Related]
39. Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions.
Mark C; Lee JS; Cui X; Yuan Y
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762027
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates.
Yao Y; Yu L; Su X; Wang Y; Li W; Wu Y; Cheng X; Zhang H; Wei X; Chen H; Zhang R; Gou L; Chen X; Xie Y; Zhang B; Zhang Y; Yang J; Wei Y
J Control Release; 2015 Dec; 220(Pt A):5-17. PubMed ID: 26439663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
